Eli Lilly and Company has announced plans to invest $6.5bn in an active pharmaceutical ingredients (API) manufacturing facility at Generation Park in Houston, in the US state of Texas. The new ...
Pharmaceutical Technology on MSN
AbbVie announces $380M investment in North Chicago API facilities
Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.
German CDMO BioSpring is building a new production facility that it hopes will become one of the world's biggest manufacturing sites for DNA- and RNA-based active pharmaceutical ingredients (API). The ...
ESTEVE CDMO, a global CDMO specializing in high-quality small-molecule APIs and pharmaceutical intermediates, began a $15.5 ...
The regulatory framework around biopharmaceutical manufacturing is exacting and continuously evolving. Companies must meet diverse global requirements while staying agile enough to deliver on ...
A rendering of the $5 billion manufacturing facility that Eli LIlly plans to build in Virginia's Goochland County near Richmond. The planned manufacturing plant will be the company's first-ever ...
BEIJING--(BUSINESS WIRE)-- Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that it has entered into a definitive Asset Purchase Agreement to acquire the ...
Upperton Pharma Solutions submits MHRA application for a new Annex 1–compliant sterile manufacturing facility, expanding clinical-scale CDMO capacity for biotech and pharma companies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results